Predictive Oncology Inc. (POAI)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 2,682 | 110,310 | 345,686 | 278,722 |
| Cost of sales | 18,221 | 45,118 | 196,919 | 152,968 |
| Gross profit (loss) | -15,539 | 65,192 | 148,767 | 125,754 |
| Sales and marketing | 268,959 | 3,633 | 246,650 | 284,421 |
| Operations, research and development | 499,715 | 520,406 | 633,422 | 893,391 |
| General and administrative | 1,875,655 | 1,828,200 | 1,582,671 | 2,137,189 |
| Total operating expenses | 2,644,329 | 2,352,239 | 2,462,743 | 3,315,001 |
| Total operating (loss) | -2,659,868 | -2,287,047 | -2,313,976 | -3,189,247 |
| Gain on derivative instruments | - | - | 7 | 359 |
| Other expense | 1,451 | 1,797 | 5,822 | 1,834 |
| Other income | 682,424 | 3,428 | 36,378 | 9,461 |
| Loss from continuing operations | -1,978,895 | -2,285,416 | -2,283,413 | - |
| Loss from discontinued operations | -91,567 | -157,457 | -811,277 | - |
| Net (loss) | -2,070,462 | -2,442,873 | -3,094,690 | -3,181,261 |
| Net (loss) per common share, basic and diluted (in dollars per share) | -0.23 | -0.34 | -0.48 | -0.68 |
| Us-gaap_weightedaveragenumberofdilutedsharesoutstanding | 9,108,984 | 7,152,221 | 6,396,221 | 4,664,771 |
| Weighted average shares used in computation basic and diluted (in shares) | 9,108,984 | 7,152,221 | 6,396,221 | 4,664,771 |